Pharmacists as providers of HIV pre-exposure prophylaxis

International Journal of Clinical Pharmacy

Volumn 34, Issue 6, 2012, Pages 803-806

  Bruno, Christine ^a   Saberi, Parya ^b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; HIV AIDS; Pharmacist Pre exposure prophylaxis; PrEP; Prevention

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR DISOPROXIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PHARMACY; DRUG MONITORING; FANCONI RENOTUBULAR SYNDROME; FOLLOW UP; HEALTH CARE UTILIZATION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTERDISCIPLINARY COMMUNICATION; MEDICAL EDUCATION; NEPHROTOXICITY; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PHARMACIST; PHARMACIST ATTITUDE; PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK REDUCTION; TUBULAR DYSFUNCTION;

AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; ATTITUDE OF HEALTH PERSONNEL; CLINICAL COMPETENCE; COMMUNITY PHARMACY SERVICES; COUNSELING; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; PHARMACISTS; PRACTICE GUIDELINES AS TOPIC; PROGRAM DEVELOPMENT; TIME FACTORS;

EID: 84872170602     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9709-0     Document Type: Review

References (30)

1. UNAIDS. UNAIDS fact sheet. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2011; Available from: Http:// www.unaids.org/en/ resources/presscentre/factsheets/.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27): 2587-99.
4. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5): 399-410.
5. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-34.
6. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-22.
7. Microbicide trials network statement on decision to discontinue use of oral Tenofovir tablets in VOICE, a major HIV prevention study in women.: Microbicide trials network; 2011 [4/15/2012]; Available from: Http://www.mtnstopshiv.org/node/3619.
8. Microbicide trials network statement on decision to discontinue use of Tenofovir gel in VOICE, a major HIV prevention study in women.: Microbicide trials network; 2011 [4/15/2012]; Available from: Http://www.mtnstopshiv.org/ node/3909.
9. Saberi P, Dong BJ, Johnson MO, Greenblatt RM, Cocohoba JM. The impact of HIV clinical pharmacists on HIV treatment outcomes: A systematic review. Patient Preference Adherence. 2012; 6:297-322.
10. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13-9.
11. Chisholm-Burns MA, Lee JK, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US pharmacists' effect as team members on patient care systematic review and meta-analyses. Med Care. 2010;48(10):923-33.
12. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: Scientific review. JAMA. 2002;288(22):2868-79. (Pubitemid 35425073)
13. Saberi P, Johnson MO. Technology-based self-care methods of improving antiretroviral adherence: A systematic review. PLoS ONE. 2011;6(11):e27533.
14. Wagner GJ, Ryan GW. Relationship between routinization of daily behaviors and medication adherence in HIV-positive drug users. AIDS Patient Care STDS. 2004;18(7):385-93. (Pubitemid 38989017)
15. Romano J, editor. PrEP 2: The next generation of drugs and technologies (Paper #69). In: 19th Conference on retroviruses and opportunistic infections. Seattle, WA; 2012. http://retroconference. org/.
16. Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011;8(2):94-103.
17. Gilchrist VJ, Stange KC, Flocke SA, McCord G, Bourguet CC. A comparison of the National Ambulatory Medical Care Survey (NAMCS) measurement approach with direct observation of outpatient visits. Med Care. 2004;42(3):276-80.
18. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: A modelling study. PLoS Med. 2011;8(11):e1001123.
19. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV preexposure prophylaxis in the United States: Impact on lifetime infection risk, clinical outcomes, and costeffectiveness. Clin Infect Dis. 2009;48(6):806-15.
20. Malik A, Abraham P, Malik N. Acute renal failure and fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect. 2005;51(2):E61-5.
21. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: A review of the evidence. Am J Kidney Dis. 2011;57(5):773-80.
22. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867-75.
23. March K, Mak M, Louie SG. Effects of pharmacists' interventions on patient outcomes in an HIV primary care clinic. Am J Health Syst Pharm. 2007;64(24):2574-8. (Pubitemid 350276298)
24. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: A systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011;171(16):1441-53.
25. HIV/AIDS Programme. Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: Recommendations for use in LexiComp. Enoxaparin (Pediatric And Neonatal Lexi-Drugs) [ No date [cited 2012 Jul 21]. Available from: Http://online.lexi.com.libproxy.lib.unc.edu/lco/action/doc/retrieve/ docid/pdh-f/129858the context of demonstration projects. In: World Health Organization, editor. 2012. http://apps.who.int/iris/bitstream/10665/75188/1/ 9789241503884-eng.pdf
26. Center for Disease Control and Prevention. CDC interim guidance on HIV pre-exposure prophylaxis. Atlanta, GA; 2012. Available from: Http://www.cdc.gov/hiv/prep/.
27. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE. 2007;2(9):e875.
28. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548-55.
29. Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA. 2010;107(27):12381-6.
30. Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: A simulation study. PLoS ONE. 2008;3(5):e2077.